Kezar Life Sciences
104 hedge funds and large institutions have $139M invested in Kezar Life Sciences in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 45 increasing their positions, 33 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
26% less capital invested
Capital invested by funds: $188M → $139M (-$48.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
73% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 44
Holders
104
Holding in Top 10
1
Calls
$1.78M
Puts
$1.48M
Top Buyers
| 1 | +$3.56M | |
| 2 | +$2.95M | |
| 3 | +$1.91M | |
| 4 |
BlackRock
New York
|
+$1.55M |
| 5 |
Two Sigma Advisers
New York
|
+$862K |
Top Sellers
| 1 | -$5.25M | |
| 2 | -$4.48M | |
| 3 | -$2.16M | |
| 4 |
Barclays
London,
United Kingdom
|
-$2M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.46M |